James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Finish Line Inc (FINL), Valeant Pharmaceuticals Intl Inc (VRX) and Best Buy Co Inc (BBY) Are 3 of Today’s Worst Stocks

Best Buy (BBY), Valeant Pharmaceuticals (VRX) and Finish Line (FINL) never even had a prayer of bullish progress on Tuesday.

Why Micron Technology, Inc. (MU) Stock Suddenly Looks So Sunny

Micron Technology investors got a scare in July. Still, MU stock remains a top pick for those who can stomach the volatility.

Best Buy Co Inc (BBY) Stock Still a Buy Despite Earnings Call Collapse

BBY stock may be too hot to handle right now, but with each quarterly report, Best Buy further proves it can compete against bigger bullies.

Advanced Micro Devices, Inc. (AMD) Stock: Not the Story That It Once Was

Advanced Micro Devices has been one of the market's biggest winners over the past two years. AMD stock is not the story stock it once was.

Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors

Vertex Pharmaceuticals has a couple of built-in things working against it. Consequently, VRTX stock is hardly a name you can buy and forget.